Sarepta CEO To Jump Ship After 'Tumultuous' Year

Earnings SnapshotOn Wednesday, Sarepta Therapeutics reported an adjusted loss of $3.58 per share, missing the Wall Street estimate loss of $1.31. Sales reached $442.93 million, beating the consensus of $391.92 million.The sales fell 33% year over year, primarily reflecting $273.8 million less in net product revenue of Elevidys as a result of lower volume following the company’s decision to suspend shipments of Elevidys to non-ambulatory patients in the U.S. in June 2025.Management TransitionIn an SEC filing ...